From Molecules to Members: Where AI Is Actually Changing Patient Outcomes

AI is beginning to reshape how pharmaceutical companies support patients beyond the molecule itself. While much of the industry conversation has focused on AI in drug discovery and R&D, increasing attention is now shifting toward how AI can improve patient outcomes across identification, engagement, adherence, and access in real-world care environments.

Across healthcare, organizations are exploring how AI can help address some of the most persistent barriers to treatment success, including delayed diagnosis, fragmented patient journeys, treatment drop-off, and administrative complexity. New approaches are emerging across patient support, care navigation, risk identification, adherence programs, and access workflows, creating opportunities to improve both patient experience and long-term outcomes.

At the same time, companies are navigating important questions around implementation, trust, governance, and how to scale these capabilities responsibly across healthcare systems and regulated environments. As AI adoption matures, the focus is increasingly shifting from experimentation to measurable operational and clinical impact.

This roundtable brings together leaders across pharma, digital health, and healthcare innovation to explore where AI is genuinely improving patient outcomes today and what separates scalable implementation from isolated pilots. The discussion will focus on practical use cases, operational lessons, and the evolving role of AI across the patient journey.

Join us to discuss:

• Where is AI delivering the clearest measurable impact for patients today?

• How are organizations using AI to improve patient identification, adherence, engagement, and access at scale?

• What operational, regulatory, and trust-related challenges continue to shape adoption and long-term success?